Lyme vaccine designed to target the 2 key outer surface proteins (Osps) involved in disease transmission for a full level of protection
Proven to induce borreliacidal antibodies that bind to OspA and OspC, forming a complex that attacks the cell membrane and kills Borrelia burgdorferi1,5
Proven to help prevent clinical disease such as arthritis – as well as at the subclinical level 5
Highly effective: no serologic evidence of exposure to Borrelia burgdorferi5
INDICATIONS:
For the vaccination of healthy dogs as an aid in the prevention of clinical disease and subclinical arthritis associated with Borrelia burgdorferi.
Recommended for use in healthy dogs 8 weeks of age or older.
Efficacy
ANTIBODY ACTIVITY
THE BORRELIACIDAL DIFFERENCE
Only Nobivac® Lyme induces borreliacidal activity against both OspA and OspC1,5,80 Not all antibody responses are the same.
“Multi-Osp protection” that induces antibodies against Osps other than OspA and OspC has not been shown to be relevant5,29,30
Other Lyme vaccines may induce antibodies against OspC, but they are not borreliacidal—meaning they don’t kill Borrelia burgdorferi
As a result, vaccines that only induce borreliacidal antibodies against OspA provide incomplete protection once OspC becomes the dominant protein expressed in the tick
Only Nobivac Lyme induces OspC borreliacidal antibodies that kill spirochetes in the tick midgut, those migrating from the midgut to the tick’s salivary glands, and those introduced into the dog80
COMPETITIVE COMPARISON
ONLY NOBIVAC® LYME OFFERS POWERFUL COMPARATIVE BENEFITS AND PROVEN SAFETY.
PREVENTS JOINT ABNORMALITIES
NOBIVAC® LYME IS PROVEN TO AID IN THE PREVENTION OF SUBCLINICAL ARTHRITIS, IN ADDITION TO CLINICAL DISEASE5
Following vaccination with Nobivac Lyme:
No Borrelia burgdorferi were found in the joint
No joint inflammation, stiffness, or lameness were observed5
40% of control dogs developed chronic joint inflammation5
27% of control dogs developed joint stiffness or lameness5
Dogs exhibited no signs of Lyme disease–associated joint abnormalities5
TICK CHALLENGE STUDY
NOBIVAC® LYME IS HIGHLY EFFECTIVE IN KILLING BORRELIA BURGDORFERI AND PREVENTING INFECTION5
Tick challenge study confirms effectiveness.5
Following vaccination with Nobivac Lyme, no B. burgdorferi were found.
The tick challenge study was a placebo-controlled trial involving thirty 8-week-old puppies. Dogs were challenged 3 weeks following second vaccination.
No items to show.
Loading…
NOBIVAC LYME IS A SAFE CHOICE
Proven safe and well tolerated in a field safety trial of more than 600 dogs
99.3% reaction-free
Since 2009, Nobivac® Lyme has been safely administered to over 4 million dogs
ADMINISTRATION AND DOSAGE
Subcutaneous injection
Two 1 mL doses given 2 to 4 weeks apart
Annual revaccination with 1 dose is recommended
Available in a 25 x 1 mL dose presentation
DISEASE INFORMATION
Canine Lyme Disease
Professional Resources and Educational Materials
Keep your clinic and staff informed and aware of diseases and outbreaks.
Lyme Disease Pet Parent Guide
Brochure
Share this printable brochure to educate pet parents about their dog’s risk for Canine Lyme Disease.
5. LaFleur RL, Dant JC, Wasmoen TL, et al. Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease. Clin Vaccine lmmunol. 2009;16(2):253-259.
29. Schwan TG, Piesman J. Vector interactions and molecular adaptations of Lyme disease and relapsing fever spirochetes associated with transmission by ticks. Emerg Infect Dis. 2002;8(2):115-121.
30. Greene CE, Straubinger K Reinhard. Borreliosis. In: Greene CE. Infectious Diseases of the Dog and Cat. 3rd ed. St. Louis, MO: Saunders/Elsevier; 2006:417-435.
80. Dant JC, LaFleur RL, Callister SM, Stahl M, et al. Ability of antibodies induced by canine Lyme disease vaccines to kill viable spirochetes. ISCAID Symposium Proceedings, Oct 2016, Bristol, UK
